Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [4][16]. Core Insights - The company achieved a revenue of 2.484 billion yuan in 2023, representing a year-on-year growth of 6.11%, and a net profit attributable to shareholders of 585 million yuan, which is an increase of 11.08% [3][13]. - The pharmaceutical sector of the company showed robust growth, with a revenue of 2.426 billion yuan, up 18.88%, and a net profit of 1.182 billion yuan, increasing by 21.58% [13]. - The company is expected to continue its growth trajectory with projected revenues of 2.869 billion yuan, 3.262 billion yuan, and 3.592 billion yuan for 2024, 2025, and 2026 respectively, alongside net profits of 708 million yuan, 813 million yuan, and 904 million yuan for the same years [4][10]. Financial Projections - Revenue growth rates are forecasted at 16% for 2024, 14% for 2025, and 10% for 2026 [10]. - The projected net profit growth rates are 21% for 2024, 15% for 2025, and 11% for 2026 [10]. - The report anticipates a decline in ROE from 20% in 2023 to 17% by 2026 [10][15]. Market Position - The company has a diverse product portfolio in the pediatric medicine sector, with notable products like "Yikexin" vitamin AD drops, which has maintained a leading market share in its category [20]. - The current stock price is 35.18 yuan, with a market capitalization of approximately 8.24 billion yuan [21]. Valuation Metrics - The report provides P/E ratios of 11.65x for 2024, 10.14x for 2025, and 9.12x for 2026, indicating a favorable valuation trend [4][10]. - The P/B ratio is projected to decrease from 2.28 in 2023 to 1.52 by 2026 [10][15]. Performance Comparison - The company's performance relative to the CSI 300 index shows a 1-month increase of 17.7%, a 3-month increase of 11.9%, and a 12-month decrease of 5.7% [13].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price based on projected earnings growth and market performance [5][11][17]. Core Insights - The company achieved a revenue of 2.484 billion yuan in 2023, representing a year-on-year growth of 6.1%, and a net profit of 585 million yuan, up 11.1% year-on-year. The fourth quarter saw significant acceleration, with a revenue of 765 million yuan, a 46.53% increase year-on-year, and a net profit of 124 million yuan, up 93.12% year-on-year [19][20]. - The company plans to distribute a cash dividend of 20 yuan per 10 shares, totaling 469 million yuan, which corresponds to a dividend payout ratio of 80% [19]. - The company is focusing on its core pharmaceutical business while continuing to divest from non-core operations, which may have a short-term impact on performance [19][20]. Financial Summary - Revenue projections for 2024-2026 are 2.809 billion yuan, 3.169 billion yuan, and 3.556 billion yuan, with year-on-year growth rates of 13.1%, 12.8%, and 12.2% respectively [5][11]. - Net profit forecasts for the same period are 671 million yuan, 763 million yuan, and 862 million yuan, with growth rates of 14.6%, 13.7%, and 13.0% respectively [5][11]. - The company's gross margin is projected to remain stable at around 86.6% to 86.7% over the next few years, with a return on equity (ROE) increasing from 19.6% in 2023 to 23.5% in 2026 [3][5][11].

Investment Rating - The report maintains a "Buy" rating for the company [14]. Core Views - The company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 2.484 billion, 585 million, and 571 million yuan respectively for 2023, showing year-on-year growth of 6.11%, 11.08%, and 7.86% [2]. - The core subsidiary, Dain Pharmaceutical, achieved revenue and net profit of 2.426 billion and 1.182 billion yuan, with year-on-year growth of 18.88% and 21.58% [2]. - The company plans to distribute a cash dividend of 20 yuan per 10 shares, with a payout ratio of 80% [2]. - The company aims for a revenue and net profit growth of no less than 10% in 2024 [2]. Summary by Sections Financial Performance - The company’s operating cash flow was 1.175 billion yuan, down 1.82% year-on-year [2]. - The basic EPS for 2023 was 2.50 yuan [2]. - In Q4 2023, the company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 765 million, 124 million, and 134 million yuan, reflecting year-on-year increases of 46.5%, 93.1%, and 73.1% [2]. Business Strategy - The company accelerated its exit from non-core businesses, which positively impacted the profitability of Dain Pharmaceutical [2]. - The company has received approval for a mid-to-long-term incentive plan from the Shandong State-owned Assets Supervision and Administration Commission, which is expected to enhance internal vitality [2]. Market Outlook - The company anticipates stable growth for its main product, Yikexin, due to a recovery in birth rates and increased adherence to daily usage [2]. - The company expects to optimize its organizational structure and drive sales for Dain Calcium and children's ibuprofen suppositories to exceed 100 million yuan in 2024 [2]. Valuation and Forecast - The net profit forecasts for 2024 and 2025 have been slightly adjusted to 669 million and 770 million yuan, respectively, reflecting a decrease of 1% and 3% from previous estimates [2]. - The estimated net profit for 2026 is projected to be 886 million yuan, with the current stock price corresponding to P/E ratios of 12, 10, and 9 for the years 2024, 2025, and 2026 [2].

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of 33.15 CNY and a target price not specified for the next six months [4]. Core Insights - The company achieved a revenue of 2.48 billion CNY in 2023, representing a growth of 6.1%, and a net profit attributable to the parent company of 590 million CNY, up by 11.1% [17]. - In Q4 2023, the company reported a significant revenue increase of 46.5% year-on-year, reaching 770 million CNY, and a net profit growth of 93.1%, amounting to 120 million CNY [17]. - The main product, Yikexin, continues to see an increase in market penetration despite a decline in newborn birth rates, with a revenue growth of over 10% in 2023 [17]. - The company aims for a revenue and net profit growth of no less than 10% in 2024 compared to 2023, focusing on promoting secondary products [17]. Financial Performance Summary - The company forecasts revenues of 2.48 billion CNY for 2023, with projections of 2.48 billion CNY, 2.85 billion CNY, 3.27 billion CNY, and 3.77 billion CNY for 2024, 2025, and 2026 respectively, indicating a growth rate of 14.66% in 2024 [5][20]. - The net profit attributable to the parent company is expected to be 585 million CNY in 2023, with projections of 655 million CNY, 754 million CNY, and 880 million CNY for the following years, reflecting a growth rate of 12.05% in 2024 [5][20]. - The report highlights a consistent gross margin of around 86% for the main product Yikexin, with a focus on maintaining stable pricing [19]. Business Strategy and Market Position - The company is focusing on its core pharmaceutical business, having exited from non-core educational partnerships and other ventures [17]. - The sales strategy has been adjusted to enhance revenue growth, particularly in the pediatric market, which is expected to continue driving performance despite demographic challenges [17]. - The company has implemented a long-term incentive plan for key personnel to support its growth strategy from 2023 to 2025 [17].

Financial Performance - The company's operating revenue for 2023 reached ¥2,484,165,699.48, representing a 6.11% increase compared to ¥2,341,075,595.24 in 2022[18] - The net profit attributable to shareholders for 2023 was ¥585,262,089.70, an increase of 11.08% from ¥526,864,048.18 in the previous year[18] - The net profit after deducting non-recurring gains and losses was ¥570,682,128.00, up 7.86% from ¥529,093,490.75 in 2022[18] - The basic earnings per share for 2023 was ¥2.50, reflecting an 11.11% increase from ¥2.25 in 2022[18] - The total assets at the end of 2023 amounted to ¥5,198,294,479.89, a 10.83% increase from ¥4,690,492,822.90 at the end of 2022[18] - The net assets attributable to shareholders increased by 15.39% to ¥2,981,885,170.31 at the end of 2023, compared to ¥2,584,088,268.61 at the end of 2022[18] - The net cash flow from operating activities for 2023 was ¥1,174,684,951.73, showing a slight decrease of 1.82% from ¥1,196,404,539.42 in 2022[18] - The weighted average return on net assets for 2023 was 21.15%, a decrease of 0.96 percentage points from 22.11% in 2022[18] Revenue Breakdown - The company's total revenue for 2023 was 2.426 billion yuan, with the pharmaceutical sector contributing 97.66% of this revenue[29] - In Q4 2023, the company reported a revenue of 765.41 million yuan, marking a significant increase compared to previous quarters[22] - The net profit attributable to shareholders for the entire year was 585.26 million yuan, with a quarterly breakdown showing a decline in Q4 to 124.47 million yuan[22] - The pharmaceutical manufacturing industry experienced a decline in revenue and profit, with a year-on-year decrease of 3.7% and 15.1% respectively[27] Product Development and Innovation - The company is focusing on children's medicine, with a significant increase in the number of pediatric drugs approved, reaching 92 varieties in 2023[28] - The company has developed a range of children's health products, including probiotics and vitamin supplements, leveraging the brand "Yike Xin" which is a well-known trademark in China[30] - The company is actively expanding its product line to include children's health foods and products, enhancing its market presence in the pediatric sector[30] - The company is committed to innovation in children's medicine, supported by favorable government policies aimed at improving pediatric healthcare services[28] - New product launches included a vitamin supplement line, with each unit containing 1500 IU of Vitamin A and 500 IU of Vitamin D3[31] - The introduction of a new calcium supplement is expected to contribute an additional 100 million RMB in revenue over the next year[31] - The company launched new products such as children's probiotics powder and bio children's toothpaste, expanding its product range in the children's health sector[43] Market Strategy and Expansion - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[32] - The company plans to invest 200 million RMB in technology upgrades to enhance production efficiency[32] - A strategic acquisition of a local competitor is anticipated to be finalized by the end of Q2 2024, expected to increase market share by 5%[32] - The company continues to maintain its market leadership position with the main product, Yike Xin Vitamin AD drops, further increasing its market share[37] - The company focuses on a "customized children's medicine" R&D philosophy, ensuring products meet children's clinical needs[37] Research and Development - Research and development efforts are focused on a new line of probiotics, with an expected launch in Q3 2024[33] - The number of R&D personnel increased by 142.27% to 235 in 2023, compared to 97 in 2022, with a significant rise in the number of bachelor's degree holders[59] - Total R&D investment for 2023 was ¥92,088,768.14, a 34.19% increase from ¥68,624,343.19 in 2022, representing 3.71% of total revenue[61] - The company has established the first children's drug research center and children's drug research institute in China, enhancing its R&D innovation capabilities[37] Corporate Governance and Compliance - The company emphasizes compliance and internal control improvements to ensure operational integrity and safety[85] - The company has received an A rating for information disclosure from the Shenzhen Stock Exchange for several consecutive years, ensuring transparency and investor communication[91] - The company has established a performance incentive mechanism for senior management, linking their compensation to the achievement of business targets[91] - The company has conducted training for its board members to ensure compliance with relevant laws and regulations[91] - The company has a clear mechanism for balancing the interests of stakeholders, including shareholders, employees, and the community[92] Environmental Responsibility - The company has maintained compliance with environmental protection regulations and holds a valid pollution discharge permit until July 29, 2025[135] - The company has implemented regular monitoring of its pollution discharge, adhering to the standards set by relevant environmental laws[135] - The company reported no instances of exceeding pollution discharge limits in its operations[136] - In 2023, the company invested 3.05 million in environmental protection and paid 0.0036 million in environmental protection tax[137] Shareholder Information - The total number of shares is 234,331,485, with 99.95% being unrestricted shares[175] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 51,544,340 shares, accounting for 22.00% of total shares[179] - The company has a total of 18,226 shareholders as of the report date[179] - The top 10 unrestricted shareholders collectively hold 86,000,000 shares, which is approximately 36.67% of total shares[181] Future Outlook - The company aims for a revenue and net profit growth of no less than 10% in 2024 compared to 2023[83] - The company plans to enhance production management and modernize production processes to ensure market supply[83] - The company will focus on increasing market share for key products like Yikexin through refined marketing strategies and brand value enhancement[84] - The company intends to accelerate the launch of new products in the treatment and children's health sectors[84]

山东华特达因健康股份有限公司 董事会战略委员会工作条例 第一章 总则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司治理结构，根据《中华人民共和国公司法》《上市公司治理准则》 《上市公司独立董事管理办法》《公司章程》等规定，制定本工作条例。 第二条 董事会战略委员会是董事会按照股东大会决议设立的专门工作机构， 主要负责对公司中长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会由五名董事组成，其中应包括三名独立董事。 第四条 战略委员会委员由董事长、过半数独立董事或者全体董事的三分之 一提名，并由董事会选举产生。 第五条 战略委员会设主任委员一名，由公司董事长担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，自动失去委员资格，并由董事会根据上述 规定补足委员人数。 第七条 战略委员会下设投资评审小组，由公司总经理任组长，公司的有关 人员及聘任的专业顾问任成员。 第八条 股东关系管理部协助董事会秘书处理战略委员会的 ...

山东华特达因健康股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部 控制监管要求（以下简称企业内部控制规范体系），结合本公司（以 下简称公司）内部控制制度和评价办法，公司董事会对公司截止 2023 年12月31日（内部控制评价报告基准日）内部控制制度的健全和有效 实施进行了全面深入的自查，在此基础上对公司的内部控制进行了自 我评价。 一、重要声明 山东华特达因健康股份有限公司 2023年度内部控制评价报告 按照企业内部控制规范体系的规定，建立健全和有效实施内部控 制，评价其有效性，并如实披露内部控制评价报告是公司董事会的责 任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重 大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、 财务报告及相关信息真实完整，提高经营效率和效果，促进实现发展 战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 证券代码：000915 证券简称：华特达因 公告编号：2024-009 山东华特达因健康股份有限公司 关于召开2023年年度股东大会的通知 1.股东大会届次：2023 年年度股东大会 2.会议召集人：公司董事会 3.会议召开的合法、合规性：董事会认为本次会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4.会议召开的日期、时间： 4.1 现场会议召开时间：2024 年 4 月 16 日下午 14:30 4.2 网络投票时间：2024 年 4 月 16 日 4.2.1 通过深圳证券交易所交易系统投票的时间为 2024 年 4 月 16 日上午 9:15－9:25，9:30－11:30，下午 13:00－15:00； 4.2.2 通过深圳证券交易所互联网系统 (http://wltp.cninfo.com.cn) 投票时间为 2024 年 4 月 16 日 09:15 至 2024 年 4 月 16 日 15:00 期间 的任意时间。 5.会议的召开方式：本次股东 ...

各位股东： 山东华特达因健康股份有限公司 独立董事 2023 年度述职报告 作为山东华特达因健康股份有限公司（以下简称华特达因或公司） 第十届董事会的独立董事，2023 年度，本人严格根据《公司法》《证 券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》及《公司章程》的规 定和要求，认真履行独立董事职责，密切关注公司事务，按时出席股 东大会、董事会、审计委员会等会议，依托专业知识为公司经营决策 和规范运作提出意见建议，认真审议董事会的各项议案，对公司重大 事项发布独立意见，充分发挥了独立董事作用，切实维护公司的整体 利益和股东特别是中小股东的合法权益。现将 2023 年度履行独立董 事职责情况报告如下： 一、独立董事个人履历、专业背景及兼职情况 吕玉芹，女，会计学教授，厦门大学会计系访问学者，山东财经 大学教师。现任公司独立董事。 报告期内，本人任职情况均符合《上市公司独立董事管理办法》 第六条规定的独立性要求，不存在影响独立性的情况。 二、出席会议情况 （一）出席董事会会议情况 （二）列席股东大会情况 2023 年，本人列席股东大会会议的情况如下： ...

证券代码：000915 证券简称：华特达因 公告编号： 2024-004 山东华特达因健康股份有限公司 第十届监事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东华特达因健康股份有限公司第十届监事会于 2024 年 3 月 4 日以电 子邮件形式发出召开第十一次会议的通知，并于 2024 年 3 月 14 日在公司 会议室召开会议。会议应参加监事 5 名，实际参加监事 5 名。会议由监事 会主席王玲女士主持。会议符合有关法律、法规、规章和《公司章程》的 规定。 （二）以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2023 年度财务决算报告》。 （三）以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2023 年度利润分配及资本公积金转增股本预案》。 （四）以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2023 年度内部控制评价报告》并发表如下意见： 公司 2023 年度内部控制评价报告的形式、内容符合有关法律、法规、 规范性文件的要求，真实、客观地 ...